OncoArendi Therapeutics Announces a License Option Agreement with University of Michigan

/PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal chemistry...

Related Keywords

Michigan State University ,Michigan ,United States ,Poland ,Warsaw ,L67 ,Eleanor Perkin ,Frazer Hall ,Adam Golebiowski ,Nicolas Beuzen ,Bryce Pilz ,Magdalena Licka ,Sandi Greenwood ,Linkedin ,Office Of The Vice ,Warsaw Stock Exchange ,University Of Michigan ,International Institute Of Molecular ,Youtube ,Innovation Partnership ,Innovation Partnerships University Of Michigan ,Business Development ,Vp Research Chemistry ,Innovation Partnerships ,Executive Director ,Strategic Alliances ,Um Innovation ,International Institute ,Cell Biology ,Oncoarendi Therapeutics ,Innovation Partnerships University ,Vice President ,David Dible ,